Funapide
- Generic Name
- Funapide
- Drug Type
- Small Molecule
- Chemical Formula
- C22H14F3NO5
- CAS Number
- 1259933-16-8
- Unique Ingredient Identifier
- A5595LHJ2L
- Background
Funapide has been used in trials studying the treatment of Pharmacokinetics, Postherpetic Neuralgia, and Osteoarthritis of the Knee.
Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Pacira Pharmaceuticals, Inc
- Target Recruit Count
- 85
- Registration Number
- NCT04826328
- Locations
- ๐บ๐ธ
Lotus Clinical Research, Huntington Hospital, Pasadena, California, United States
A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT02365636
- Locations
- ๐บ๐ธ
Teva Investigational Site 13053, Atlanta, Georgia, United States
๐บ๐ธTeva Investigational Site 13064, Miami, Florida, United States
๐บ๐ธTeva Investigational Site 13335, Miami, Florida, United States
Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02215941
- Locations
- ๐บ๐ธ
Teva Investigational Site 12961, Lenexa, Kansas, United States
A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 389
- Registration Number
- NCT02068599
- Locations
- ๐บ๐ธ
Teva Investigational Site 12236, Memphis, Tennessee, United States
๐บ๐ธTeva Investigational Site 12246, Eustis, Florida, United States
๐บ๐ธTeva Investigational Site 12255, Ormond Beach, Florida, United States
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
- Conditions
- Inherited ErythromelalgiaPrimary Erythromelalgia
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2014-04-14
- Lead Sponsor
- Xenon Pharmaceuticals Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01486446
- Locations
- ๐บ๐ธ
Pinnacle Research Group, LLC., Anniston, Alabama, United States
A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Xenon Pharmaceuticals Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT01195636
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.